Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTM-3566 in Advanced Solid Tumors
NCT07266285Phase 1Recruiting
- Sponsor
- Bantam Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BTM-3566 in solid tumor (advanced stage), sponsored by Bantam Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
BTM-3566
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07266285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266285.